{ "company_details": [ { "company_id": "0000899923", "feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/feature_distribution/feature_distribution_0000899923.svg", "graph_url": "https://www.realrate-archive.com/us_medicinal_products/2010/graphs/IME_0000899923.svg", "logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000899923.svg", "logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000899923_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0000899923_main_keyfigs.svg", "name": "Myriad Genetics INC", "rank": 1, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Myriad Genetics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Myriad Genetics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 98% points.The greatest weakness of Myriad Genetics INC is the variable Assets, Current, reducing the Economic Capital Ratio by 9.2% points.

The company's Economic Capital Ratio, given in the ranking table, is 304%, being 127% points above the market average of 177%.", "report_url": "https://www.realrate-archive.com/us_medicinal_products/2010/report/0000899923_2011_Myriad_Genetics_INC.pdf", "shrinked_graph_json": { "2010": { "Other Liabilities": "-1.22", "Liabilities": "69.0", "Stockholders Equity": "98.4", "ECR before LimitedLiability": "125", "Liabilities, Current": "33.4", "Liabilities, Non-Current": "45.6", "Goodwill": "1.45", "Assets": "-6.03", "Property, Plant and Equipment, Net": "1.03", "Assets, Current": "-9.25", "Assets, Non-Current": "-0.952", "Other Expenses": "27.3", "Expenses": "28.0", "Revenues": "14.8", "Net Income": "44.5", "General and Administrative Expense": "-1.98", "Research and Development": "2.70", "Other Revenues": "14.8", "Other Net Income": "3.09", "Comprehensive Net Income": "44.6", "Economic Capital Ratio": "127" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0000899923_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "473,976", "Assets, Non-Current": "85,154", "General and Administrative Expense": "205,700", "Goodwill": "2,052", "Liabilities, Current": "27,466", "Liabilities, Non-Current": "0", "Other Assets": "9,404", "Other Compr. Net Income": "0", "Other Expenses": "-11,469", "Other Liabilities": "8,800", "Other Net Income": "0", "Other Revenues": "368,407", "Property, Plant and Equipment, Net": "23,261", "Research and Development": "21,873" }, "output_variables": { "Liabilities": "36,266", "Assets": "593,847", "Expenses": "216,104", "Revenues": "368,407", "Stockholders Equity": "557,581", "Net Income": "152,303", "Comprehensive Net Income": "152,303", "BaseVar": "607,312", "ECR before LimitedLiability": "291%", "Economic Capital Ratio": "304%" } } }, "top_rated": true, "trend": null, "value": 3.037248474942705, "company_index": "https://www.realrate-archive.com/us_medicinal_products/2010/industry_indexes/0000899923.svg", "analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/equity/0000899923.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/profit_loss/0000899923.svg" }, { "company_id": "0000794172", "feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/feature_distribution/feature_distribution_0000794172.svg", "graph_url": "https://www.realrate-archive.com/us_medicinal_products/2010/graphs/IME_0000794172.svg", "logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000794172.svg", "logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000794172_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0000794172_main_keyfigs.svg", "name": "Meridian Bioscience INC", "rank": 2, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Meridian Bioscience INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Meridian Bioscience INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 74% points.The greatest weakness of Meridian Bioscience INC is the variable Other Expenses, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 279%, being 101% points above the market average of 177%.", "report_url": "https://www.realrate-archive.com/us_medicinal_products/2010/report/0000794172_2011_Meridian_Bioscience_INC.pdf", "shrinked_graph_json": { "2009": { "Liabilities, Non-Current": "1.55", "Liabilities": "21.8", "Stockholders Equity": "51.4", "ECR before LimitedLiability": "62.8", "Liabilities, Current": "18.5", "Other Liabilities": "2.31", "Property, Plant and Equipment, Net": "-0.449", "Assets": "2.99", "Other Assets": "-1.08", "Assets, Current": "3.82", "Assets, Non-Current": "0.609", "Goodwill": "0.588", "General and Administrative Expense": "29.9", "Expenses": "20.1", "Revenues": "-1.56", "Net Income": "18.9", "Other Expenses": "-6.87", "Research and Development": "-3.78", "Other Revenues": "-1.56", "Comprehensive Net Income": "19.0", "Economic Capital Ratio": "62.0" }, "2010": { "Other Liabilities": "6.11", "Liabilities": "74.1", "Stockholders Equity": "61.8", "ECR before LimitedLiability": "99.5", "Liabilities, Current": "29.2", "Liabilities, Non-Current": "50.9", "Goodwill": "0.732", "Assets": "0.843", "Assets, Current": "1.06", "Assets, Non-Current": "1.69", "Other Assets": "-1.80", "Other Expenses": "-35.7", "Expenses": "-1.55", "Revenues": "29.3", "Net Income": "31.7", "General and Administrative Expense": "28.8", "Research and Development": "2.56", "Other Revenues": "29.3", "Other Net Income": "4.05", "Comprehensive Net Income": "31.8", "Economic Capital Ratio": "101" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0000794172_strength_weakness.svg", "table_records": { "2009": { "input_variables": { "Assets, Current": "117,147", "Assets, Non-Current": "18,376", "General and Administrative Expense": "35,576", "Goodwill": "17,183", "Liabilities, Current": "16,752", "Liabilities, Non-Current": "0", "Other Assets": "-17,183", "Other Compr. Net Income": "0", "Other Expenses": "72,055", "Other Liabilities": "0", "Other Net Income": "544", "Other Revenues": "148,274", "Property, Plant and Equipment, Net": "20,474", "Research and Development": "8,428" }, "output_variables": { "Liabilities": "16,752", "Assets": "155,997", "Expenses": "116,059", "Revenues": "148,274", "Stockholders Equity": "139,245", "Net Income": "32,759", "Comprehensive Net Income": "32,759", "BaseVar": "218,813", "ECR before LimitedLiability": "259%", "Economic Capital Ratio": "278%" } }, "2010": { "input_variables": { "Assets, Current": "94,020", "Assets, Non-Current": "38,048", "General and Administrative Expense": "37,527", "Goodwill": "36,809", "Liabilities, Current": "14,147", "Liabilities, Non-Current": "0", "Other Assets": "-36,809", "Other Compr. Net Income": "0", "Other Expenses": "70,518", "Other Liabilities": "0", "Other Net Income": "262", "Other Revenues": "143,000", "Property, Plant and Equipment, Net": "22,717", "Research and Development": "8,570" }, "output_variables": { "Liabilities": "14,147", "Assets": "154,785", "Expenses": "116,615", "Revenues": "143,000", "Stockholders Equity": "140,638", "Net Income": "26,647", "Comprehensive Net Income": "26,647", "BaseVar": "214,404", "ECR before LimitedLiability": "260%", "Economic Capital Ratio": "279%" } } }, "top_rated": true, "trend": -1.0, "value": 2.78572257501562, "company_index": "https://www.realrate-archive.com/us_medicinal_products/2010/industry_indexes/0000794172.svg", "analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/equity/0000794172.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/profit_loss/0000794172.svg" }, { "company_id": "0000037785", "feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/feature_distribution/feature_distribution_0000037785.svg", "graph_url": "https://www.realrate-archive.com/us_medicinal_products/2010/graphs/IME_0000037785.svg", "logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000037785.svg", "logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000037785_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0000037785_main_keyfigs.svg", "name": "FMC CORP", "rank": 3, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of FMC CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of FMC CORP compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 37% points.The greatest weakness of FMC CORP is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 209%, being 32% points above the market average of 177%.", "report_url": "https://www.realrate-archive.com/us_medicinal_products/2010/report/0000037785_2011_FMC_CORP.pdf", "shrinked_graph_json": { "2009": { "Liabilities, Non-Current": "1.10", "Liabilities": "-12.3", "Stockholders Equity": "20.1", "ECR before LimitedLiability": "9.42", "Liabilities, Current": "-15.4", "Other Liabilities": "1.64", "Property, Plant and Equipment, Net": "6.68", "Assets": "10.3", "Other Assets": "4.39", "Assets, Current": "-1.53", "Goodwill": "0.287", "General and Administrative Expense": "-28.3", "Expenses": "12.9", "Revenues": "-12.5", "Comprehensive Net Income": "-0.188", "Other Expenses": "39.8", "Research and Development": "-0.0822", "Other Revenues": "-12.5", "Other Net Income": "-0.721", "Other Compr. Net Income": "-0.157", "Economic Capital Ratio": "8.70" }, "2010": { "Other Liabilities": "4.05", "Liabilities": "23.4", "Stockholders Equity": "10.1", "ECR before LimitedLiability": "29.8", "Liabilities, Current": "-21.9", "Liabilities, Non-Current": "36.5", "Other Expenses": "15.1", "Expenses": "-3.63", "Net Income": "14.6", "General and Administrative Expense": "-24.5", "Research and Development": "5.36", "Other Revenues": "14.0", "Revenues": "14.0", "Goodwill": "-7.02", "Property, Plant and Equipment, Net": "5.42", "Assets, Current": "-4.49", "Assets, Non-Current": "-2.70", "Other Assets": "8.69", "Other Net Income": "4.20", "Comprehensive Net Income": "14.0", "Economic Capital Ratio": "31.8" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0000037785_strength_weakness.svg", "table_records": { "2009": { "input_variables": { "Assets, Current": "1,487,700", "Assets, Non-Current": "211,400", "General and Administrative Expense": "2,265,900", "Goodwill": "209,500", "Liabilities, Current": "709,200", "Liabilities, Non-Current": "0", "Other Assets": "263,100", "Other Compr. Net Income": "-13,400", "Other Expenses": "213,000", "Other Liabilities": "0", "Other Net Income": "-15,700", "Other Revenues": "2,826,200", "Property, Plant and Equipment, Net": "964,500", "Research and Development": "92,800" }, "output_variables": { "Liabilities": "709,200", "Assets": "3,136,200", "Expenses": "2,571,700", "Revenues": "2,826,200", "Stockholders Equity": "2,427,000", "Net Income": "238,800", "Comprehensive Net Income": "232,100", "BaseVar": "4,636,200", "ECR before LimitedLiability": "185%", "Economic Capital Ratio": "225%" } }, "2010": { "input_variables": { "Assets, Current": "1,646,200", "Assets, Non-Current": "223,700", "General and Administrative Expense": "2,476,800", "Goodwill": "194,400", "Liabilities, Current": "963,400", "Liabilities, Non-Current": "0", "Other Assets": "337,100", "Other Compr. Net Income": "-44,900", "Other Expenses": "323,400", "Other Liabilities": "0", "Other Net Income": "36,500", "Other Revenues": "3,116,300", "Property, Plant and Equipment, Net": "918,500", "Research and Development": "100,500" }, "output_variables": { "Liabilities": "963,400", "Assets": "3,319,900", "Expenses": "2,900,700", "Revenues": "3,116,300", "Stockholders Equity": "2,356,500", "Net Income": "252,100", "Comprehensive Net Income": "229,650", "BaseVar": "5,190,850", "ECR before LimitedLiability": "161%", "Economic Capital Ratio": "209%" } } }, "top_rated": false, "trend": -1.0, "value": 2.0888015326893106, "company_index": "https://www.realrate-archive.com/us_medicinal_products/2010/industry_indexes/0000037785.svg", "analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/equity/0000037785.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/profit_loss/0000037785.svg" }, { "company_id": "0000874716", "feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/feature_distribution/feature_distribution_0000874716.svg", "graph_url": "https://www.realrate-archive.com/us_medicinal_products/2010/graphs/IME_0000874716.svg", "logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000874716.svg", "logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000874716_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0000874716_main_keyfigs.svg", "name": "Idexx Laboratories INC DE", "rank": 4, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Idexx Laboratories INC DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Idexx Laboratories INC DE compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 33% points.The greatest weakness of Idexx Laboratories INC DE is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 203%, being 26% points above the market average of 177%.", "report_url": "https://www.realrate-archive.com/us_medicinal_products/2010/report/0000874716_2011_Idexx_Laboratories_INC_DE.pdf", "shrinked_graph_json": { "2010": { "Other Liabilities": "4.39", "Liabilities": "21.9", "Stockholders Equity": "-14.3", "ECR before LimitedLiability": "23.6", "Liabilities, Current": "-18.4", "Liabilities, Non-Current": "32.6", "Assets": "-11.3", "Property, Plant and Equipment, Net": "0.217", "Assets, Current": "-8.67", "Assets, Non-Current": "28.2", "Other Assets": "-18.8", "Other Expenses": "21.1", "Expenses": "-8.82", "Revenues": "28.5", "Net Income": "23.0", "General and Administrative Expense": "-32.3", "Research and Development": "1.98", "Other Revenues": "28.5", "Other Net Income": "3.49", "Comprehensive Net Income": "23.1", "Economic Capital Ratio": "25.6" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0000874716_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "460,591", "Assets, Non-Current": "436,553", "General and Administrative Expense": "830,914", "Goodwill": "204,864", "Liabilities, Current": "285,112", "Liabilities, Non-Current": "37,751", "Other Assets": "-406,589", "Other Compr. Net Income": "0", "Other Expenses": "63,224", "Other Liabilities": "0", "Other Net Income": "663", "Other Revenues": "1,103,392", "Property, Plant and Equipment, Net": "201,725", "Research and Development": "68,597" }, "output_variables": { "Liabilities": "322,863", "Assets": "897,144", "Expenses": "962,735", "Revenues": "1,103,392", "Stockholders Equity": "574,281", "Net Income": "141,320", "Comprehensive Net Income": "141,320", "BaseVar": "1,643,398", "ECR before LimitedLiability": "152%", "Economic Capital Ratio": "203%" } } }, "top_rated": false, "trend": null, "value": 2.027402529821438, "company_index": "https://www.realrate-archive.com/us_medicinal_products/2010/industry_indexes/0000874716.svg", "analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/equity/0000874716.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/profit_loss/0000874716.svg" }, { "company_id": "0001056358", "feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/feature_distribution/feature_distribution_0001056358.svg", "graph_url": "https://www.realrate-archive.com/us_medicinal_products/2010/graphs/IME_0001056358.svg", "logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001056358.png", "logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001056358_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0001056358_main_keyfigs.svg", "name": "Mannatech INC", "rank": 5, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Mannatech INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mannatech INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 70% points.The greatest weakness of Mannatech INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is 150%, being 27% points below the market average of 177%.", "report_url": "https://www.realrate-archive.com/us_medicinal_products/2010/report/0001056358_2011_Mannatech_INC.pdf", "shrinked_graph_json": { "2009": { "Liabilities, Non-Current": "-3.85", "Liabilities": "-9.05", "Stockholders Equity": "-140", "ECR before LimitedLiability": "-70.0", "Other Liabilities": "-5.76", "Property, Plant and Equipment, Net": "-17.3", "Assets": "-58.1", "Other Assets": "9.04", "Assets, Current": "-42.8", "Assets, Non-Current": "-13.3", "Goodwill": "-14.0", "General and Administrative Expense": "3.92", "Expenses": "-62.6", "Revenues": "34.1", "Net Income": "-34.3", "Other Expenses": "-72.3", "Research and Development": "7.47", "Other Revenues": "34.1", "Comprehensive Net Income": "-34.2", "Other Net Income": "1.13", "Economic Capital Ratio": "-70.7" }, "2010": { "Liabilities": "65.1", "Stockholders Equity": "-124", "ECR before LimitedLiability": "-29.4", "Liabilities, Current": "11.6", "Liabilities, Non-Current": "59.2", "Goodwill": "-32.3", "Assets": "-66.0", "Property, Plant and Equipment, Net": "-17.8", "Assets, Current": "-42.4", "Assets, Non-Current": "-19.2", "Other Assets": "15.5", "Other Expenses": "-110", "Expenses": "-90.9", "Revenues": "69.9", "Net Income": "2.46", "General and Administrative Expense": "0.961", "Research and Development": "20.1", "Other Revenues": "69.9", "Other Net Income": "7.69", "Comprehensive Net Income": "2.63", "Economic Capital Ratio": "-27.4" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0001056358_strength_weakness.svg", "table_records": { "2009": { "input_variables": { "Assets, Current": "64,485", "Assets, Non-Current": "2,503", "General and Administrative Expense": "116,810", "Goodwill": "0", "Liabilities, Current": "42,679", "Liabilities, Non-Current": "3,348", "Other Assets": "8,170", "Other Compr. Net Income": "0", "Other Expenses": "191,782", "Other Liabilities": "4,991", "Other Net Income": "1,519", "Other Revenues": "289,705", "Property, Plant and Equipment, Net": "27,144", "Research and Development": "0" }, "output_variables": { "Liabilities": "51,018", "Assets": "102,302", "Expenses": "308,592", "Revenues": "289,705", "Stockholders Equity": "51,284", "Net Income": "-17,368", "Comprehensive Net Income": "-17,368", "BaseVar": "376,568", "ECR before LimitedLiability": "69%", "Economic Capital Ratio": "145%" } }, "2010": { "input_variables": { "Assets, Current": "55,215", "Assets, Non-Current": "3,054", "General and Administrative Expense": "95,411", "Goodwill": "0", "Liabilities, Current": "32,240", "Liabilities, Non-Current": "4,996", "Other Assets": "4,705", "Other Compr. Net Income": "0", "Other Expenses": "143,734", "Other Liabilities": "3,107", "Other Net Income": "441", "Other Revenues": "228,088", "Property, Plant and Equipment, Net": "18,449", "Research and Development": "0" }, "output_variables": { "Liabilities": "40,343", "Assets": "81,423", "Expenses": "239,145", "Revenues": "228,088", "Stockholders Equity": "41,080", "Net Income": "-10,616", "Comprehensive Net Income": "-10,616", "BaseVar": "294,720", "ECR before LimitedLiability": "75%", "Economic Capital Ratio": "150%" } } }, "top_rated": false, "trend": -2.0, "value": 1.4968599934555056, "company_index": "https://www.realrate-archive.com/us_medicinal_products/2010/industry_indexes/0001056358.svg", "analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/equity/0001056358.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/profit_loss/0001056358.svg" }, { "company_id": "0000074303", "feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/feature_distribution/feature_distribution_0000074303.svg", "graph_url": "https://www.realrate-archive.com/us_medicinal_products/2010/graphs/IME_0000074303.svg", "logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000074303.svg", "logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000074303_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0000074303_main_keyfigs.svg", "name": "OLIN Corp", "rank": 6, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of OLIN Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OLIN Corp compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 21% points.The greatest weakness of OLIN Corp is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 149%, being 28% points below the market average of 177%.", "report_url": "https://www.realrate-archive.com/us_medicinal_products/2010/report/0000074303_2011_OLIN_Corp.pdf", "shrinked_graph_json": { "2010": { "Liabilities": "-32.8", "Stockholders Equity": "-28.9", "ECR before LimitedLiability": "-30.5", "Liabilities, Current": "1.73", "Liabilities, Non-Current": "-36.2", "Goodwill": "-4.33", "Assets": "-4.43", "Property, Plant and Equipment, Net": "15.0", "Assets, Current": "-12.7", "Assets, Non-Current": "-7.23", "Other Assets": "9.43", "Other Expenses": "21.0", "Expenses": "8.06", "Revenues": "-3.03", "Net Income": "9.56", "General and Administrative Expense": "-19.2", "Research and Development": "8.02", "Other Revenues": "-3.03", "Other Net Income": "4.53", "Comprehensive Net Income": "9.63", "Economic Capital Ratio": "-28.5" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0000074303_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "882,800", "Assets, Non-Current": "72,300", "General and Administrative Expense": "1,484,300", "Goodwill": "300,300", "Liabilities, Current": "391,000", "Liabilities, Non-Current": "803,900", "Other Assets": "118,300", "Other Compr. Net Income": "0", "Other Expenses": "71,700", "Other Liabilities": "23,500", "Other Net Income": "34,900", "Other Revenues": "1,585,900", "Property, Plant and Equipment, Net": "675,000", "Research and Development": "0" }, "output_variables": { "Liabilities": "1,218,400", "Assets": "2,048,700", "Expenses": "1,556,000", "Revenues": "1,585,900", "Stockholders Equity": "830,300", "Net Income": "64,800", "Comprehensive Net Income": "64,800", "BaseVar": "3,221,950", "ECR before LimitedLiability": "74%", "Economic Capital Ratio": "149%" } } }, "top_rated": false, "trend": null, "value": 1.486312480087053, "company_index": "https://www.realrate-archive.com/us_medicinal_products/2010/industry_indexes/0000074303.svg", "analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/equity/0000074303.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/profit_loss/0000074303.svg" }, { "company_id": "0001315695", "feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/feature_distribution/feature_distribution_0001315695.svg", "graph_url": "https://www.realrate-archive.com/us_medicinal_products/2010/graphs/IME_0001315695.svg", "logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0001315695_main_keyfigs.svg", "name": "Rockwood Holdings Inc", "rank": 7, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Rockwood Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rockwood Holdings Inc compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 24% points.The greatest weakness of Rockwood Holdings Inc is the variable Liabilities, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 132%, being 46% points below the market average of 177%.", "report_url": "https://www.realrate-archive.com/us_medicinal_products/2010/report/0001315695_2011_Rockwood_Holdings_Inc.pdf", "shrinked_graph_json": { "2010": { "Other Liabilities": "-13.2", "Liabilities": "-55.1", "Stockholders Equity": "-39.2", "ECR before LimitedLiability": "-47.5", "Liabilities, Current": "-6.11", "Liabilities, Non-Current": "-32.9", "Goodwill": "14.7", "Assets": "-0.454", "Property, Plant and Equipment, Net": "18.1", "Assets, Current": "-19.3", "Assets, Non-Current": "-10.1", "Other Assets": "4.39", "Other Expenses": "23.9", "Expenses": "21.3", "Revenues": "-9.01", "Net Income": "11.4", "General and Administrative Expense": "-9.75", "Research and Development": "7.73", "Other Revenues": "-9.01", "Comprehensive Net Income": "11.5", "Economic Capital Ratio": "-45.5" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0001315695_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "1,618,600", "Assets, Non-Current": "38,500", "General and Administrative Expense": "2,817,400", "Goodwill": "1,464,700", "Liabilities, Current": "1,095,800", "Liabilities, Non-Current": "1,799,600", "Other Assets": "35,600", "Other Compr. Net Income": "0", "Other Expenses": "-8,100", "Other Liabilities": "477,500", "Other Net Income": "-133,800", "Other Revenues": "3,191,600", "Property, Plant and Equipment, Net": "1,566,900", "Research and Development": "0" }, "output_variables": { "Liabilities": "3,372,900", "Assets": "4,724,300", "Expenses": "2,809,300", "Revenues": "3,191,600", "Stockholders Equity": "1,351,400", "Net Income": "248,500", "Comprehensive Net Income": "248,500", "BaseVar": "7,115,950", "ECR before LimitedLiability": "52%", "Economic Capital Ratio": "132%" } } }, "top_rated": false, "trend": null, "value": 1.3158506283427087, "company_index": "https://www.realrate-archive.com/us_medicinal_products/2010/industry_indexes/0001315695.svg", "analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/equity/0001315695.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/profit_loss/0001315695.svg" }, { "company_id": "0001145460", "feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/feature_distribution/feature_distribution_0001145460.svg", "graph_url": "https://www.realrate-archive.com/us_medicinal_products/2010/graphs/IME_0001145460.svg", "logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0001145460_main_keyfigs.svg", "name": "Alere INC", "rank": 8, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Alere INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alere INC compared to the market average is the variable Goodwill, increasing the Economic Capital Ratio by 55% points.The greatest weakness of Alere INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 60% points.

The company's Economic Capital Ratio, given in the ranking table, is 130%, being 47% points below the market average of 177%.", "report_url": "https://www.realrate-archive.com/us_medicinal_products/2010/report/0001145460_2011_Alere_INC.pdf", "shrinked_graph_json": { "2010": { "Other Liabilities": "2.41", "Liabilities": "-50.0", "Stockholders Equity": "-12.7", "ECR before LimitedLiability": "-49.1", "Liabilities, Current": "5.50", "Liabilities, Non-Current": "-59.8", "Goodwill": "54.9", "Assets": "25.5", "Property, Plant and Equipment, Net": "-9.25", "Assets, Current": "-24.8", "Assets, Non-Current": "-7.27", "Other Assets": "4.17", "Expenses": "15.9", "Revenues": "-27.8", "Net Income": "-10.9", "General and Administrative Expense": "9.38", "Research and Development": "4.56", "Other Revenues": "-27.8", "Other Net Income": "3.19", "Comprehensive Net Income": "-10.8", "Economic Capital Ratio": "-47.1" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0001145460_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "1,194,257", "Assets, Non-Current": "153,361", "General and Administrative Expense": "1,966,801", "Goodwill": "4,538,881", "Liabilities, Current": "782,858", "Liabilities, Non-Current": "2,969,790", "Other Assets": "53,365", "Other Compr. Net Income": "0", "Other Expenses": "1,115,861", "Other Liabilities": "0", "Other Net Income": "44,701", "Other Revenues": "2,155,347", "Property, Plant and Equipment, Net": "390,510", "Research and Development": "133,278" }, "output_variables": { "Liabilities": "3,752,648", "Assets": "6,330,374", "Expenses": "3,215,940", "Revenues": "2,155,347", "Stockholders Equity": "2,577,726", "Net Income": "-1,015,892", "Comprehensive Net Income": "-1,015,892", "BaseVar": "7,749,505", "ECR before LimitedLiability": "50%", "Economic Capital Ratio": "130%" } } }, "top_rated": false, "trend": null, "value": 1.2997086613263749, "company_index": "https://www.realrate-archive.com/us_medicinal_products/2010/industry_indexes/0001145460.svg", "analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/equity/0001145460.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/profit_loss/0001145460.svg" }, { "company_id": "0001307954", "feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/feature_distribution/feature_distribution_0001307954.svg", "graph_url": "https://www.realrate-archive.com/us_medicinal_products/2010/graphs/IME_0001307954.svg", "logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0001307954.svg", "logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0001307954_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0001307954_main_keyfigs.svg", "name": "Huntsman CORP", "rank": 9, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Huntsman CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Huntsman CORP compared to the market average is the variable General and Administrative Expense, increasing the Economic Capital Ratio by 32% points.The greatest weakness of Huntsman CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 68% points.

The company's Economic Capital Ratio, given in the ranking table, is 115%, being 62% points below the market average of 177%.", "report_url": "https://www.realrate-archive.com/us_medicinal_products/2010/report/0001307954_2011_Huntsman_CORP.pdf", "shrinked_graph_json": { "2010": { "Other Liabilities": "-2.03", "Liabilities": "-45.4", "Stockholders Equity": "-67.7", "ECR before LimitedLiability": "-63.6", "Liabilities, Current": "2.22", "Liabilities, Non-Current": "-45.6", "Goodwill": "-21.9", "Assets": "-28.8", "Property, Plant and Equipment, Net": "24.7", "Assets, Current": "-25.7", "Assets, Non-Current": "-6.92", "Other Assets": "7.77", "Other Revenues": "5.95", "Revenues": "5.95", "Net Income": "8.75", "Comprehensive Net Income": "8.76", "Research and Development": "8.63", "Other Net Income": "2.35", "Other Expenses": "-53.9", "General and Administrative Expense": "32.3", "Economic Capital Ratio": "-61.6" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0001307954_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "4,008,000", "Assets, Non-Current": "729,000", "General and Administrative Expense": "861,000", "Goodwill": "199,000", "Liabilities, Current": "2,053,000", "Liabilities, Non-Current": "4,493,000", "Other Assets": "173,000", "Other Compr. Net Income": "-15,000", "Other Expenses": "8,086,000", "Other Liabilities": "318,000", "Other Net Income": "-122,000", "Other Revenues": "9,252,000", "Property, Plant and Equipment, Net": "3,605,000", "Research and Development": "151,000" }, "output_variables": { "Liabilities": "6,864,000", "Assets": "8,714,000", "Expenses": "9,098,000", "Revenues": "9,252,000", "Stockholders Equity": "1,850,000", "Net Income": "32,000", "Comprehensive Net Income": "24,500", "BaseVar": "17,032,500", "ECR before LimitedLiability": "33%", "Economic Capital Ratio": "115%" } } }, "top_rated": false, "trend": null, "value": 1.1547668469233385, "company_index": "https://www.realrate-archive.com/us_medicinal_products/2010/industry_indexes/0001307954.svg", "analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/equity/0001307954.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/profit_loss/0001307954.svg" }, { "company_id": "0000722104", "feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/feature_distribution/feature_distribution_0000722104.svg", "graph_url": "https://www.realrate-archive.com/us_medicinal_products/2010/graphs/IME_0000722104.svg", "logo_url": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000.png", "logo_url_256x256": "https://www.realrate-archive.com/us_medicinal_products/logos/0000000000_256x256.png", "main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0000722104_main_keyfigs.svg", "name": "Savient Pharmaceuticals INC", "rank": 10, "regression_plot": "No stock price available", "report_text": "The relative strengths and weaknesses of Savient Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Savient Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 52% points.The greatest weakness of Savient Pharmaceuticals INC is the variable Net Income, reducing the Economic Capital Ratio by 108% points.

The company's Economic Capital Ratio, given in the ranking table, is 102%, being 75% points below the market average of 177%.", "report_url": "https://www.realrate-archive.com/us_medicinal_products/2010/report/0000722104_2011_Savient_Pharmaceuticals_INC.pdf", "shrinked_graph_json": { "2010": { "Liabilities": "13.5", "Stockholders Equity": "21.7", "ECR before LimitedLiability": "-77.3", "Liabilities, Current": "-19.7", "Liabilities, Non-Current": "17.4", "Goodwill": "-23.3", "Assets": "20.8", "Property, Plant and Equipment, Net": "-21.3", "Assets, Current": "52.4", "Assets, Non-Current": "-12.2", "Other Assets": "16.9", "Other Expenses": "17.2", "Expenses": "-23.4", "Revenues": "-68.8", "Net Income": "-108", "General and Administrative Expense": "7.69", "Research and Development": "-48.4", "Other Revenues": "-68.8", "Other Net Income": "-28.3", "Comprehensive Net Income": "-108", "Economic Capital Ratio": "-75.3" } }, "strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/plot_over_time/0000722104_strength_weakness.svg", "table_records": { "2010": { "input_variables": { "Assets, Current": "71,325", "Assets, Non-Current": "1,284", "General and Administrative Expense": "24,981", "Goodwill": "0", "Liabilities, Current": "18,052", "Liabilities, Non-Current": "0", "Other Assets": "4,200", "Other Compr. Net Income": "0", "Other Expenses": "2,664", "Other Liabilities": "0", "Other Net Income": "-17,134", "Other Revenues": "4,028", "Property, Plant and Equipment, Net": "809", "Research and Development": "32,358" }, "output_variables": { "Liabilities": "18,052", "Assets": "77,618", "Expenses": "60,003", "Revenues": "4,028", "Stockholders Equity": "59,566", "Net Income": "-73,109", "Comprehensive Net Income": "-73,109", "BaseVar": "88,418", "ECR before LimitedLiability": "18%", "Economic Capital Ratio": "102%" } } }, "top_rated": false, "trend": null, "value": 1.0179913066744173, "company_index": "https://www.realrate-archive.com/us_medicinal_products/2010/industry_indexes/0000722104.svg", "analysing_equity": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/equity/0000722104.svg", "analysing_profit_loss": "https://www.realrate-archive.com/us_medicinal_products/2010/analytics/profit_loss/0000722104.svg" } ], "feature_distribution_plot": "https://www.realrate-archive.com/us_medicinal_products/2010/feature_distribution/feature_distribution.svg", "final_var_label": "Economic Capital Ratio", "industry_box": [ [ "Revenues", "21.1 B" ], [ "Assets", "26.9 B" ], [ "Expenses", "21.2 B" ], [ "Stockholders Equity", "10.3 B" ] ], "industry_id": "us_medicinal_products", "industry_label": "Medicinal Products", "num_companies": 10, "num_top_companies": 2, "ecr_records": { "2009": { "0000794172": { "rank": 1, "ecr": "278" }, "0000037785": { "rank": 2, "ecr": "225" }, "0001056358": { "rank": 3, "ecr": "145" } }, "2010": { "0000899923": { "rank": 1, "ecr": "304" }, "0000794172": { "rank": 2, "ecr": "279" }, "0000037785": { "rank": 3, "ecr": "209" }, "0000874716": { "rank": 4, "ecr": "203" }, "0001056358": { "rank": 5, "ecr": "150" }, "0000074303": { "rank": 6, "ecr": "149" }, "0001315695": { "rank": 7, "ecr": "132" }, "0001145460": { "rank": 8, "ecr": "130" }, "0001307954": { "rank": 9, "ecr": "115" }, "0000722104": { "rank": 10, "ecr": "102" } } }, "rating_box": [ [ "Top rated", "2 of 10" ], [ "Best, worst rating", "304 %, 102 %" ], [ "New companies", "7" ] ], "regression_plot": null, "scentences": [ "FMC CORP climbed -1 positions from 2 to 3 due to its excellent Liabilities, Non-Current.", "Mannatech INC lost 2 positions from 3 to 5 due to its bad Stockholders Equity.", "Myriad Genetics INC entered the 2011 ranking at rank 1, making it the best newcomer." ], "url_segment": "2011-us-medicinal-products", "year": 2011, "feature_importance": "https://www.realrate-archive.com/us_medicinal_products/2010/feature_importance/feature_importance.svg", "obs_ecr": { "0000037785": { "2011": { "obs_EconomicCapitalRatio": 1.9637052598410045 }, "2012": { "obs_EconomicCapitalRatio": 2.2187352745223867 }, "2013": { "obs_EconomicCapitalRatio": 2.0998789372222704 }, "2014": { "obs_EconomicCapitalRatio": 1.641537801830664 }, "2015": { "obs_EconomicCapitalRatio": 1.0723385245823782 }, "2016": { "obs_EconomicCapitalRatio": 1.6108835909734713 }, "2017": { "obs_EconomicCapitalRatio": 1.8056499758638158 }, "2018": { "obs_EconomicCapitalRatio": 1.2287717494570867 }, "2019": { "obs_EconomicCapitalRatio": 1.7092843014022376 }, "2020": { "obs_EconomicCapitalRatio": 1.9284688934634902 }, "2021": { "obs_EconomicCapitalRatio": 1.6770740146552199 }, "2022": { "obs_EconomicCapitalRatio": 1.834863173719622 }, "2023": { "obs_EconomicCapitalRatio": 0.9158901623685305 } }, "0001056358": { "2011": { "obs_EconomicCapitalRatio": 0.18783097649548078 }, "2012": { "obs_EconomicCapitalRatio": 0.3196597323000155 }, "2013": { "obs_EconomicCapitalRatio": 0.7370346023559032 }, "2014": { "obs_EconomicCapitalRatio": 1.0406162753683343 }, "2015": { "obs_EconomicCapitalRatio": 0.7323625964348088 }, "2016": { "obs_EconomicCapitalRatio": 0.753066668490597 }, "2017": { "obs_EconomicCapitalRatio": 0.5232637759318683 }, "2018": { "obs_EconomicCapitalRatio": 0.7338326629079127 }, "2019": { "obs_EconomicCapitalRatio": 0.6223996309643847 }, "2020": { "obs_EconomicCapitalRatio": 0.6307022721006672 }, "2021": { "obs_EconomicCapitalRatio": 1.4634619355072704 }, "2022": { "obs_EconomicCapitalRatio": 0.820186420650827 }, "2023": { "obs_EconomicCapitalRatio": 0.42412588511273297 }, "2024": { "obs_EconomicCapitalRatio": 0.6963642400059836 }, "2025": { "obs_EconomicCapitalRatio": 0.47545840734858463 } }, "0000074303": { "2011": { "obs_EconomicCapitalRatio": 0.5221628155371295 }, "2012": { "obs_EconomicCapitalRatio": 0.5016941351915414 }, "2013": { "obs_EconomicCapitalRatio": 0.7067485666124749 }, "2014": { "obs_EconomicCapitalRatio": 0.5800072775923082 }, "2015": { "obs_EconomicCapitalRatio": 0.26932516949788865 }, "2016": { "obs_EconomicCapitalRatio": 0.4320388824657905 }, "2017": { "obs_EconomicCapitalRatio": 0.5856850809511247 }, "2018": { "obs_EconomicCapitalRatio": 0.3494568183316394 }, "2019": { "obs_EconomicCapitalRatio": 0.2952768225185927 }, "2020": { "obs_EconomicCapitalRatio": 0.48260038439530095 }, "2021": { "obs_EconomicCapitalRatio": 1.1559183950584917 }, "2022": { "obs_EconomicCapitalRatio": 0.9955682298738215 }, "2023": { "obs_EconomicCapitalRatio": 0.939616887252673 }, "2024": { "obs_EconomicCapitalRatio": 0.5703504787209263 }, "2025": { "obs_EconomicCapitalRatio": 0.3659536949506686 } }, "0001307954": { "2011": { "obs_EconomicCapitalRatio": 0.18938003655153654 }, "2012": { "obs_EconomicCapitalRatio": 0.3154058367754545 }, "2013": { "obs_EconomicCapitalRatio": 0.4780017903384275 }, "2014": { "obs_EconomicCapitalRatio": 0.384792729924332 }, "2018": { "obs_EconomicCapitalRatio": 0.5095392164405845 }, "2019": { "obs_EconomicCapitalRatio": 0.6235372978487372 }, "2020": { "obs_EconomicCapitalRatio": 0.6619386066086855 }, "2021": { "obs_EconomicCapitalRatio": 0.8463350886179348 }, "2022": { "obs_EconomicCapitalRatio": 0.7115101902118032 }, "2023": { "obs_EconomicCapitalRatio": 0.7137373813546445 }, "2024": { "obs_EconomicCapitalRatio": 0.5244746605193847 }, "2025": { "obs_EconomicCapitalRatio": 0.3141640811372542 } }, "0000874716": { "2011": { "obs_EconomicCapitalRatio": 5.678189619495421 }, "2012": { "obs_EconomicCapitalRatio": 6.62985272864075 }, "2013": { "obs_EconomicCapitalRatio": 5.637583008591172 }, "2014": { "obs_EconomicCapitalRatio": 5.3378472038789315 }, "2015": { "obs_EconomicCapitalRatio": 4.359021798706142 }, "2016": { "obs_EconomicCapitalRatio": 6.735635676724686 }, "2017": { "obs_EconomicCapitalRatio": 7.882744231502931 }, "2018": { "obs_EconomicCapitalRatio": 10.363928250251758 }, "2019": { "obs_EconomicCapitalRatio": 12.865202087427075 }, "2020": { "obs_EconomicCapitalRatio": 21.31825222425334 }, "2021": { "obs_EconomicCapitalRatio": 26.268423294328166 }, "2022": { "obs_EconomicCapitalRatio": 13.828898358817076 }, "2023": { "obs_EconomicCapitalRatio": 18.252894151087883 }, "2024": { "obs_EconomicCapitalRatio": 13.560026821642062 }, "2025": { "obs_EconomicCapitalRatio": 21.570882602865723 } }, "0000899923": { "2011": { "obs_EconomicCapitalRatio": 5.286603114326388 }, "2012": { "obs_EconomicCapitalRatio": 5.947932077650038 }, "2013": { "obs_EconomicCapitalRatio": 4.09378437010731 }, "2014": { "obs_EconomicCapitalRatio": 5.490507086553531 }, "2015": { "obs_EconomicCapitalRatio": 6.944372988710795 }, "2016": { "obs_EconomicCapitalRatio": 2.339757271124506 }, "2017": { "obs_EconomicCapitalRatio": 2.8740508316547966 }, "2018": { "obs_EconomicCapitalRatio": 3.0914586906825567 }, "2019": { "obs_EconomicCapitalRatio": 1.9630081673133826 }, "2021": { "obs_EconomicCapitalRatio": 2.606632146369483 }, "2022": { "obs_EconomicCapitalRatio": 1.7004450020894173 }, "2023": { "obs_EconomicCapitalRatio": 2.215290054291016 }, "2024": { "obs_EconomicCapitalRatio": 1.823931615329854 }, "2025": { "obs_EconomicCapitalRatio": 1.1682929523136367 } }, "0000885462": { "2011": { "obs_EconomicCapitalRatio": 0.477594589877508 }, "2012": { "obs_EconomicCapitalRatio": 0.2925556156090612 }, "2013": { "obs_EconomicCapitalRatio": 0.5361327962905387 }, "2014": { "obs_EconomicCapitalRatio": 0.2505281175819798 }, "2015": { "obs_EconomicCapitalRatio": 0.43387267254203915 }, "2016": { "obs_EconomicCapitalRatio": 0.5022902813318385 }, "2017": { "obs_EconomicCapitalRatio": 0.34065719753844165 }, "2018": { "obs_EconomicCapitalRatio": 0.22997496410238202 }, "2019": { "obs_EconomicCapitalRatio": 0.1659154208060553 }, "2020": { "obs_EconomicCapitalRatio": 0.26901950354979465 }, "2021": { "obs_EconomicCapitalRatio": 0.2838385361778253 }, "2022": { "obs_EconomicCapitalRatio": 0.2067987843408893 }, "2023": { "obs_EconomicCapitalRatio": 0.11983703427943283 }, "2024": { "obs_EconomicCapitalRatio": 0.06649192725741328 } }, "0001054905": { "2011": { "obs_EconomicCapitalRatio": 1.4579074706215878 }, "2012": { "obs_EconomicCapitalRatio": 1.7997149963883579 }, "2013": { "obs_EconomicCapitalRatio": 1.964317914289097 }, "2014": { "obs_EconomicCapitalRatio": 1.4734327096252018 }, "2015": { "obs_EconomicCapitalRatio": 1.8591617658964918 }, "2016": { "obs_EconomicCapitalRatio": 2.185789648905985 }, "2017": { "obs_EconomicCapitalRatio": 1.7880006703658458 }, "2018": { "obs_EconomicCapitalRatio": 1.5318875768219857 }, "2019": { "obs_EconomicCapitalRatio": 2.6164701172132556 }, "2020": { "obs_EconomicCapitalRatio": 2.4715120247319406 }, "2021": { "obs_EconomicCapitalRatio": 2.201354917056966 }, "2022": { "obs_EconomicCapitalRatio": 2.262740511238834 } }, "0001141240": { "2011": { "obs_EconomicCapitalRatio": 5.502360615827963 }, "2012": { "obs_EconomicCapitalRatio": 2.4369547526522646 }, "2013": { "obs_EconomicCapitalRatio": 11.581935819020808 }, "2014": { "obs_EconomicCapitalRatio": 7.5454875670319685 }, "2015": { "obs_EconomicCapitalRatio": 5.634514556207966 }, "2016": { "obs_EconomicCapitalRatio": 5.458003060729301 }, "2017": { "obs_EconomicCapitalRatio": 6.7960569922086025 }, "2018": { "obs_EconomicCapitalRatio": 4.351678898468258 }, "2019": { "obs_EconomicCapitalRatio": 4.24355658618375 }, "2020": { "obs_EconomicCapitalRatio": 3.6370684560423614 }, "2021": { "obs_EconomicCapitalRatio": 4.458556769073509 }, "2022": { "obs_EconomicCapitalRatio": 3.1784879275692157 }, "2023": { "obs_EconomicCapitalRatio": 3.3273144132655075 }, "2024": { "obs_EconomicCapitalRatio": 2.3178398698599603 }, "2025": { "obs_EconomicCapitalRatio": 5.890984282760348 } }, "0000768408": { "2011": { "obs_EconomicCapitalRatio": 5.715133312847765 }, "2012": { "obs_EconomicCapitalRatio": 2.3017018284798714 }, "2013": { "obs_EconomicCapitalRatio": 1.425277475641039 }, "2014": { "obs_EconomicCapitalRatio": 1.8803973873475237 }, "2015": { "obs_EconomicCapitalRatio": 1.4412650279511978 }, "2016": { "obs_EconomicCapitalRatio": 1.0071551396713583 }, "2017": { "obs_EconomicCapitalRatio": 1.1153169457297638 }, "2018": { "obs_EconomicCapitalRatio": 0.924011890899123 }, "2019": { "obs_EconomicCapitalRatio": 0.6138635192851674 }, "2020": { "obs_EconomicCapitalRatio": 0.7664774974857526 }, "2021": { "obs_EconomicCapitalRatio": 0.871286208388657 }, "2022": { "obs_EconomicCapitalRatio": 0.27420450138403873 }, "2023": { "obs_EconomicCapitalRatio": 0.26934082796065434 }, "2024": { "obs_EconomicCapitalRatio": 0.14158948221183076 } }, "0000787253": { "2011": { "obs_EconomicCapitalRatio": 2.526353775920534 }, "2012": { "obs_EconomicCapitalRatio": 1.3160543270878733 }, "2014": { "obs_EconomicCapitalRatio": 1.1960142220158665 }, "2015": { "obs_EconomicCapitalRatio": 2.1497060764213507 }, "2016": { "obs_EconomicCapitalRatio": 1.6596075035664513 }, "2017": { "obs_EconomicCapitalRatio": 1.820275172276164 }, "2018": { "obs_EconomicCapitalRatio": 1.4250126839098163 }, "2019": { "obs_EconomicCapitalRatio": 0.8714870157425864 }, "2020": { "obs_EconomicCapitalRatio": 0.8186963761612863 }, "2021": { "obs_EconomicCapitalRatio": 0.9963355986876283 }, "2022": { "obs_EconomicCapitalRatio": 0.4935946735445941 }, "2023": { "obs_EconomicCapitalRatio": 0.4463203114259345 }, "2024": { "obs_EconomicCapitalRatio": 0.21764563032603712 } }, "0000896264": { "2011": { "obs_EconomicCapitalRatio": 2.987080353491173 }, "2012": { "obs_EconomicCapitalRatio": 2.8476111068826424 }, "2013": { "obs_EconomicCapitalRatio": 4.5724271596679005 }, "2015": { "obs_EconomicCapitalRatio": 7.320772852461824 }, "2016": { "obs_EconomicCapitalRatio": 2.5202405198959905 }, "2017": { "obs_EconomicCapitalRatio": 5.400078197143357 }, "2018": { "obs_EconomicCapitalRatio": 7.8437625855710635 }, "2019": { "obs_EconomicCapitalRatio": 5.208661448534275 }, "2022": { "obs_EconomicCapitalRatio": 2.794889038132937 }, "2023": { "obs_EconomicCapitalRatio": 2.6884992698433976 }, "2024": { "obs_EconomicCapitalRatio": 1.4865583930571376 } }, "0001086303": { "2012": { "obs_EconomicCapitalRatio": 0.050408616621473605 }, "2013": { "obs_EconomicCapitalRatio": 0.3592188918384183 }, "2014": { "obs_EconomicCapitalRatio": 0.5202291430401021 }, "2018": { "obs_EconomicCapitalRatio": 75.60385532024324 }, "2023": { "obs_EconomicCapitalRatio": 5.825073650532234 } }, "0001134765": { "2013": { "obs_EconomicCapitalRatio": 84.83868255676903 }, "2014": { "obs_EconomicCapitalRatio": 93.1111485713505 }, "2015": { "obs_EconomicCapitalRatio": 199.2672351710133 }, "2016": { "obs_EconomicCapitalRatio": 216.93321071912177 }, "2017": { "obs_EconomicCapitalRatio": 60.02178473917171 }, "2018": { "obs_EconomicCapitalRatio": 12.822507944414118 }, "2019": { "obs_EconomicCapitalRatio": 455.3649181791688 }, "2020": { "obs_EconomicCapitalRatio": 668.0565240083155 }, "2021": { "obs_EconomicCapitalRatio": 3.604592501252785 }, "2022": { "obs_EconomicCapitalRatio": 3.9983823737615998 }, "2023": { "obs_EconomicCapitalRatio": 4.432317616137024 }, "2024": { "obs_EconomicCapitalRatio": 2.934393508015559 }, "2025": { "obs_EconomicCapitalRatio": 7.17941906968866 } }, "0001310630": { "2011": { "obs_EconomicCapitalRatio": 118.5920894437218 }, "2012": { "obs_EconomicCapitalRatio": 90.47339849409984 }, "2013": { "obs_EconomicCapitalRatio": 72.75975087344283 }, "2014": { "obs_EconomicCapitalRatio": 60.05301282758653 }, "2015": { "obs_EconomicCapitalRatio": 46.147679617159916 }, "2016": { "obs_EconomicCapitalRatio": 37.04924725418156 }, "2017": { "obs_EconomicCapitalRatio": 30.944660874575487 }, "2019": { "obs_EconomicCapitalRatio": 85.1712892994052 }, "2020": { "obs_EconomicCapitalRatio": 24.70852870017063 }, "2023": { "obs_EconomicCapitalRatio": 90.31718007058653 }, "2024": { "obs_EconomicCapitalRatio": 18.12427183566627 }, "2025": { "obs_EconomicCapitalRatio": 15.788052734849284 } }, "0001374328": { "2011": { "obs_EconomicCapitalRatio": 1.843040104492836 }, "2012": { "obs_EconomicCapitalRatio": 1.406513180725925 }, "2013": { "obs_EconomicCapitalRatio": 2.5629155706742086 }, "2014": { "obs_EconomicCapitalRatio": 3.2200542353297674 }, "2015": { "obs_EconomicCapitalRatio": 1.2965403490667224 }, "2016": { "obs_EconomicCapitalRatio": 0.9353195843240845 }, "2017": { "obs_EconomicCapitalRatio": 0.4394415225694401 }, "2018": { "obs_EconomicCapitalRatio": 0.9423630321081906 }, "2019": { "obs_EconomicCapitalRatio": 2.6565609559613317 }, "2020": { "obs_EconomicCapitalRatio": 9.948498907383927 }, "2022": { "obs_EconomicCapitalRatio": 4.994024545393992 }, "2023": { "obs_EconomicCapitalRatio": 2.2965761578523303 }, "2024": { "obs_EconomicCapitalRatio": 3.6843422189586965 }, "2025": { "obs_EconomicCapitalRatio": 1.821523711080343 } }, "0001386570": { "2011": { "obs_EconomicCapitalRatio": 8.338141326290996 }, "2012": { "obs_EconomicCapitalRatio": 8.392729648541112 }, "2013": { "obs_EconomicCapitalRatio": 26.219216155099797 }, "2019": { "obs_EconomicCapitalRatio": 8.591985092140105 }, "2020": { "obs_EconomicCapitalRatio": 10.063615397839953 }, "2021": { "obs_EconomicCapitalRatio": 6.442513704241379 }, "2022": { "obs_EconomicCapitalRatio": 2.8215640716473835 }, "2023": { "obs_EconomicCapitalRatio": 2.6556157143776864 }, "2024": { "obs_EconomicCapitalRatio": 9.237391489557004 }, "2025": { "obs_EconomicCapitalRatio": 7.630478708487693 } }, "0000711377": { "2011": { "obs_EconomicCapitalRatio": 5.820904874555574 }, "2012": { "obs_EconomicCapitalRatio": 7.7503288458074415 }, "2013": { "obs_EconomicCapitalRatio": 10.377788751403328 }, "2014": { "obs_EconomicCapitalRatio": 9.392743252183534 }, "2015": { "obs_EconomicCapitalRatio": 10.034849829461312 }, "2016": { "obs_EconomicCapitalRatio": 10.103194801881472 }, "2017": { "obs_EconomicCapitalRatio": 14.452119850474038 }, "2018": { "obs_EconomicCapitalRatio": 8.566992718065048 }, "2019": { "obs_EconomicCapitalRatio": 9.17563055998759 }, "2020": { "obs_EconomicCapitalRatio": 9.88631712937769 }, "2021": { "obs_EconomicCapitalRatio": 9.735723882656965 }, "2022": { "obs_EconomicCapitalRatio": 5.856026588966056 } }, "0000744218": { "2011": { "obs_EconomicCapitalRatio": 1.8965131603685095 }, "2012": { "obs_EconomicCapitalRatio": 5.333855573956268 }, "2013": { "obs_EconomicCapitalRatio": 10.230725112264693 }, "2014": { "obs_EconomicCapitalRatio": 11.553522232787866 }, "2015": { "obs_EconomicCapitalRatio": 8.22074780222265 }, "2016": { "obs_EconomicCapitalRatio": 1.4980547705405713 }, "2017": { "obs_EconomicCapitalRatio": 2.021188969442516 }, "2018": { "obs_EconomicCapitalRatio": 0.3696518300152486 }, "2019": { "obs_EconomicCapitalRatio": 0.48016381910130834 }, "2020": { "obs_EconomicCapitalRatio": 5.262656817463394 }, "2021": { "obs_EconomicCapitalRatio": 7.793666490988671 }, "2022": { "obs_EconomicCapitalRatio": 10.883731101898258 }, "2023": { "obs_EconomicCapitalRatio": 7.286143405813059 } }, "0000811641": { "2011": { "obs_EconomicCapitalRatio": 2.136690390726703 }, "2012": { "obs_EconomicCapitalRatio": 1.849039798017059 }, "2013": { "obs_EconomicCapitalRatio": 2.010189247495304 }, "2014": { "obs_EconomicCapitalRatio": 2.34474040567545 }, "2015": { "obs_EconomicCapitalRatio": 2.4785461696903734 }, "2016": { "obs_EconomicCapitalRatio": 1.9865134449583703 }, "2017": { "obs_EconomicCapitalRatio": 1.6949100276813254 }, "2018": { "obs_EconomicCapitalRatio": 1.7852801061870174 }, "2019": { "obs_EconomicCapitalRatio": 1.5240857269328754 }, "2020": { "obs_EconomicCapitalRatio": 1.7195565413895542 }, "2021": { "obs_EconomicCapitalRatio": 2.367024189117178 }, "2022": { "obs_EconomicCapitalRatio": 1.6292353884860042 }, "2023": { "obs_EconomicCapitalRatio": 1.1622002191801761 }, "2025": { "obs_EconomicCapitalRatio": 1.9024392280197613 } }, "0000907654": { "2011": { "obs_EconomicCapitalRatio": 0.0 }, "2013": { "obs_EconomicCapitalRatio": 2.2151696375266194 }, "2014": { "obs_EconomicCapitalRatio": 1.8158262418443614 }, "2015": { "obs_EconomicCapitalRatio": 1.28497308211443 }, "2016": { "obs_EconomicCapitalRatio": 1.0818389503384735 }, "2017": { "obs_EconomicCapitalRatio": 1.3032495591532267 }, "2018": { "obs_EconomicCapitalRatio": 0.6794655548784231 }, "2019": { "obs_EconomicCapitalRatio": 1.027889384231902 }, "2020": { "obs_EconomicCapitalRatio": 0.7572061787169263 }, "2021": { "obs_EconomicCapitalRatio": 0.6116995115921646 }, "2022": { "obs_EconomicCapitalRatio": 0.8326777832489594 } }, "0000926617": { "2011": { "obs_EconomicCapitalRatio": 0.936747166508658 }, "2012": { "obs_EconomicCapitalRatio": 3.2987773210340476 }, "2013": { "obs_EconomicCapitalRatio": 3.310250104657181 }, "2014": { "obs_EconomicCapitalRatio": 4.317801092124128 }, "2015": { "obs_EconomicCapitalRatio": 7.655824111431128 }, "2016": { "obs_EconomicCapitalRatio": 8.900428301796273 }, "2017": { "obs_EconomicCapitalRatio": 20.503758003717643 }, "2018": { "obs_EconomicCapitalRatio": 3.2888488055796508 }, "2019": { "obs_EconomicCapitalRatio": 8.83333842031845 }, "2020": { "obs_EconomicCapitalRatio": 45.47327065656971 }, "2021": { "obs_EconomicCapitalRatio": 7.933579854593867 }, "2022": { "obs_EconomicCapitalRatio": 2.857163597552752 }, "2023": { "obs_EconomicCapitalRatio": 3.901740100848714 }, "2024": { "obs_EconomicCapitalRatio": 1.8703748454852225 } }, "0000949858": { "2011": { "obs_EconomicCapitalRatio": 0.0 }, "2012": { "obs_EconomicCapitalRatio": 0.0 }, "2013": { "obs_EconomicCapitalRatio": 0.0 }, "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2015": { "obs_EconomicCapitalRatio": 0.0 }, "2016": { "obs_EconomicCapitalRatio": 0.0 }, "2017": { "obs_EconomicCapitalRatio": 2.518997627887442 }, "2018": { "obs_EconomicCapitalRatio": 0.7422482465262066 }, "2019": { "obs_EconomicCapitalRatio": 0.35343147435010663 }, "2020": { "obs_EconomicCapitalRatio": 1.3239430629183255 }, "2021": { "obs_EconomicCapitalRatio": 2.1718168400927897 }, "2022": { "obs_EconomicCapitalRatio": 0.9346116862802668 } }, "0000009326": { "2012": { "obs_EconomicCapitalRatio": 5.656587982913678 }, "2013": { "obs_EconomicCapitalRatio": 7.79966708407013 }, "2014": { "obs_EconomicCapitalRatio": 2.9084764827636236 }, "2015": { "obs_EconomicCapitalRatio": 2.8483648673741246 }, "2016": { "obs_EconomicCapitalRatio": 3.648755401436501 }, "2017": { "obs_EconomicCapitalRatio": 3.787889348418163 }, "2019": { "obs_EconomicCapitalRatio": 4.035821822778718 }, "2020": { "obs_EconomicCapitalRatio": 4.735832660774467 }, "2021": { "obs_EconomicCapitalRatio": 6.878840843345401 }, "2022": { "obs_EconomicCapitalRatio": 3.32579266803479 }, "2023": { "obs_EconomicCapitalRatio": 4.327515096253764 }, "2024": { "obs_EconomicCapitalRatio": 5.341740174720832 }, "2025": { "obs_EconomicCapitalRatio": 4.797400698850301 } }, "0000073290": { "2012": { "obs_EconomicCapitalRatio": 1.8838244732270972 }, "2013": { "obs_EconomicCapitalRatio": 1.6432390281123206 }, "2014": { "obs_EconomicCapitalRatio": 1.9239557658497293 }, "2015": { "obs_EconomicCapitalRatio": 2.669474942212977 }, "2016": { "obs_EconomicCapitalRatio": 5.686234008415378 }, "2017": { "obs_EconomicCapitalRatio": 12.426535116483144 }, "2018": { "obs_EconomicCapitalRatio": 6.023112230267755 }, "2019": { "obs_EconomicCapitalRatio": 8.71810270966778 }, "2020": { "obs_EconomicCapitalRatio": 5.758603861413226 }, "2021": { "obs_EconomicCapitalRatio": 7.171288908839465 }, "2022": { "obs_EconomicCapitalRatio": 6.5820905271862715 }, "2023": { "obs_EconomicCapitalRatio": 2.3689702399551757 }, "2024": { "obs_EconomicCapitalRatio": 0.8328246370864223 } }, "0000093314": { "2012": { "obs_EconomicCapitalRatio": 17.719277991697727 }, "2013": { "obs_EconomicCapitalRatio": 16.172791954794842 }, "2014": { "obs_EconomicCapitalRatio": 17.12412941207431 }, "2015": { "obs_EconomicCapitalRatio": 17.094853012648368 }, "2016": { "obs_EconomicCapitalRatio": 7.646119704869701 }, "2017": { "obs_EconomicCapitalRatio": 7.835630820870826 }, "2018": { "obs_EconomicCapitalRatio": 5.69389490958303 }, "2020": { "obs_EconomicCapitalRatio": 10.494231213006202 }, "2021": { "obs_EconomicCapitalRatio": 9.325363829987609 }, "2022": { "obs_EconomicCapitalRatio": 7.038632118707036 }, "2023": { "obs_EconomicCapitalRatio": 1.692739776873626 }, "2024": { "obs_EconomicCapitalRatio": 2.538095829463765 }, "2025": { "obs_EconomicCapitalRatio": 1.267911014322384 } }, "0001504678": { "2021": { "obs_EconomicCapitalRatio": 21.761860501462678 }, "2023": { "obs_EconomicCapitalRatio": 7.712264043121101 }, "2024": { "obs_EconomicCapitalRatio": 4.273885183694472 } }, "0001321834": { "2014": { "obs_EconomicCapitalRatio": 0.0 }, "2018": { "obs_EconomicCapitalRatio": 0.0 }, "2019": { "obs_EconomicCapitalRatio": 0.0 }, "2020": { "obs_EconomicCapitalRatio": 0.0 }, "2021": { "obs_EconomicCapitalRatio": 0.0 }, "2022": { "obs_EconomicCapitalRatio": 0.0 }, "2023": { "obs_EconomicCapitalRatio": 0.0 }, "2024": { "obs_EconomicCapitalRatio": 0.25079529133050554 }, "2025": { "obs_EconomicCapitalRatio": 0.6661650116856921 } }, "0001627223": { "2015": { "obs_EconomicCapitalRatio": 0.11531512461593406 }, "2016": { "obs_EconomicCapitalRatio": 0.5041107353269599 }, "2017": { "obs_EconomicCapitalRatio": 0.9792616137942283 }, "2018": { "obs_EconomicCapitalRatio": 0.5037929444305274 }, "2019": { "obs_EconomicCapitalRatio": 0.33457321143007535 }, "2020": { "obs_EconomicCapitalRatio": 0.5470460275521768 }, "2021": { "obs_EconomicCapitalRatio": 0.6499364328629865 }, "2022": { "obs_EconomicCapitalRatio": 0.5809502304277893 } }, "0001552189": { "2022": { "obs_EconomicCapitalRatio": 0.051966645127577905 }, "2023": { "obs_EconomicCapitalRatio": 0.16744960403999323 } }, "0001653477": { "2016": { "obs_EconomicCapitalRatio": 2.9965230053381644 }, "2017": { "obs_EconomicCapitalRatio": 3.7915367442390675 }, "2018": { "obs_EconomicCapitalRatio": 2.922808947052789 }, "2019": { "obs_EconomicCapitalRatio": 1.959253575073628 }, "2020": { "obs_EconomicCapitalRatio": 1.5143708031469667 }, "2021": { "obs_EconomicCapitalRatio": 1.3249257731828572 }, "2022": { "obs_EconomicCapitalRatio": 1.1004777222391815 }, "2023": { "obs_EconomicCapitalRatio": 0.7369191018660393 }, "2024": { "obs_EconomicCapitalRatio": 0.7736223011953498 }, "2025": { "obs_EconomicCapitalRatio": 1.3076730606119293 } }, "0001586554": { "2016": { "obs_EconomicCapitalRatio": 0.48058259081278015 }, "2018": { "obs_EconomicCapitalRatio": 1.4962619054091728 }, "2019": { "obs_EconomicCapitalRatio": 0.891464023479221 }, "2020": { "obs_EconomicCapitalRatio": 0.5424015614406267 }, "2021": { "obs_EconomicCapitalRatio": 0.4143393157324369 }, "2022": { "obs_EconomicCapitalRatio": 0.23894685685583492 }, "2023": { "obs_EconomicCapitalRatio": 0.10261033505859418 } }, "0001642380": { "2016": { "obs_EconomicCapitalRatio": 21.72207919293821 }, "2017": { "obs_EconomicCapitalRatio": 21.3709545386487 }, "2019": { "obs_EconomicCapitalRatio": 4.529546805842379 }, "2021": { "obs_EconomicCapitalRatio": 1.6309746744371012 }, "2022": { "obs_EconomicCapitalRatio": 0.4521509520900019 }, "2023": { "obs_EconomicCapitalRatio": 0.3591924761920325 } }, "0001652130": { "2016": { "obs_EconomicCapitalRatio": 3.199958649296 }, "2017": { "obs_EconomicCapitalRatio": 3.3067347442937 }, "2018": { "obs_EconomicCapitalRatio": 2.957402513032481 }, "2019": { "obs_EconomicCapitalRatio": 4.091879539456148 }, "2020": { "obs_EconomicCapitalRatio": 9.369785151591545 }, "2021": { "obs_EconomicCapitalRatio": 12.780171311702386 }, "2022": { "obs_EconomicCapitalRatio": 3.4031614469183005 } }, "0001708035": { "2017": { "obs_EconomicCapitalRatio": 0.4391634781975079 }, "2018": { "obs_EconomicCapitalRatio": 0.3838203482983531 }, "2019": { "obs_EconomicCapitalRatio": 0.48129649674893044 }, "2020": { "obs_EconomicCapitalRatio": 0.6013288369758395 }, "2021": { "obs_EconomicCapitalRatio": 0.8978665871292398 }, "2022": { "obs_EconomicCapitalRatio": 0.7567918532035208 }, "2023": { "obs_EconomicCapitalRatio": 0.7709750516345434 }, "2024": { "obs_EconomicCapitalRatio": 0.6033738356189466 }, "2025": { "obs_EconomicCapitalRatio": 1.152367959333189 } }, "0001522767": { "2017": { "obs_EconomicCapitalRatio": 4.28352597297854 }, "2018": { "obs_EconomicCapitalRatio": 11.84484946199016 }, "2019": { "obs_EconomicCapitalRatio": 1.6647152363257145 }, "2020": { "obs_EconomicCapitalRatio": 1.8939909944990796 }, "2023": { "obs_EconomicCapitalRatio": 0.7154614969958419 }, "2024": { "obs_EconomicCapitalRatio": 0.2730915686403338 }, "2025": { "obs_EconomicCapitalRatio": 0.22748336782703915 } }, "0001731348": { "2020": { "obs_EconomicCapitalRatio": 1.0343902967287055 }, "2021": { "obs_EconomicCapitalRatio": 0.9151944120269997 }, "2022": { "obs_EconomicCapitalRatio": 0.5292237994678327 }, "2023": { "obs_EconomicCapitalRatio": 0.5873188828335296 }, "2024": { "obs_EconomicCapitalRatio": 0.48595324362468467 } }, "0001656472": { "2020": { "obs_EconomicCapitalRatio": 2.4846037628909143 }, "2021": { "obs_EconomicCapitalRatio": 2.1068641047612973 }, "2022": { "obs_EconomicCapitalRatio": 1.5226433295914465 }, "2023": { "obs_EconomicCapitalRatio": 1.2617458734917226 }, "2024": { "obs_EconomicCapitalRatio": 1.2298351104750205 }, "2025": { "obs_EconomicCapitalRatio": 1.6798919218022832 } }, "0001737927": { "2020": { "obs_EconomicCapitalRatio": 2.2413009969523126 }, "2021": { "obs_EconomicCapitalRatio": 0.722105723732089 }, "2022": { "obs_EconomicCapitalRatio": 0.49880311487341555 } }, "0001754195": { "2025": { "obs_EconomicCapitalRatio": 0.6572335792654658 } }, "0001756390": { "2021": { "obs_EconomicCapitalRatio": 1.6656381745552173 }, "2022": { "obs_EconomicCapitalRatio": 0.2766604451340951 }, "2023": { "obs_EconomicCapitalRatio": 0.2521606213881799 }, "2024": { "obs_EconomicCapitalRatio": 0.09670274277596863 }, "2025": { "obs_EconomicCapitalRatio": 0.15693027900478207 } }, "0001813814": { "2022": { "obs_EconomicCapitalRatio": 1.017428702644666 } }, "0001850902": { "2021": { "obs_EconomicCapitalRatio": 5.898441690535421 }, "2022": { "obs_EconomicCapitalRatio": 1.4117684980890728 } }, "0001906324": { "2022": { "obs_EconomicCapitalRatio": 3.794104483895451 }, "2023": { "obs_EconomicCapitalRatio": 0.8130511823271402 }, "2024": { "obs_EconomicCapitalRatio": 0.6055538968322262 }, "2025": { "obs_EconomicCapitalRatio": 0.4114130862644389 } } } }